Hookipa, Gilead partner to develop immunotherapies against HIV and HepB

Gilead Sciences Inc. (NASDAQ:GILD) gained exclusive, worldwide rights from Hookipa Biotech AG (Vienna, Austria) to use its

Read the full 173 word article

User Sign In